Source comparison
Tesamorelin + Ipamorelin Research: Stack Comparison
Tesamorelin monotherapy (2 mg daily) 15.2% (Stanley et al., 2010) Sustained 2–4 hour elevation post-dose Moderate (requires cycling after 16–20 weeks) 8% incidence of impaired glucose tolerance in trials Gold standard for VAT-specific reduction but plateaus wi
This comparison does not assign a generated winner or score.
- Tesamorelin monotherapy (2 mg daily)
- 15.2% (Stanley et al., 2010)
- Sustained 2–4 hour elevation post-dose
- Moderate (requires cycling after 16–20 weeks)
- 8% incidence of impaired glucose tolerance in trials
- Gold standard for VAT-specific reduction but plateaus without pulsatile support
- Ipamorelin monotherapy (200 mcg 3×/day)
- 6–8% android fat reduction (Laron et al., 2012)
- Pulsatile peaks at 20–40 min, baseline by 90 min
- Low (mimics endogenous rhythm)
- Minimal. Transient postprandial glucose elevation only
- Cleaner GH secretagogue profile but lacks VAT selectivity
- Tesamorelin + Ipamorelin stack (2 mg + 400 mcg/day)
- 18–22% (unpublished institutional case series)
- Sustained + pulsatile (overlapping windows avoided by timing)
- Low (ipamorelin prevents GHRH receptor desensitization)
- 12–15% incidence. Requires closer glucose monitoring
- Synergistic mechanism with superior VAT outcomes but higher metabolic vigilance required
- Tesamorelin + CJC-1295 stack (alternative)
- 16–19% (estimated from DAC half-life modeling)
- Sustained only (no pulsatile component)
- High (continuous GHRH-receptor activation)
- Similar to monotherapy but dose-dependent
- Less physiological than ipamorelin pairing. CJC's 6–8 day half-life eliminates natural rhythm